111Skin, a high-end skincare label, began its journey from a surgical necessity to a global phenomenon, fueled by innovative formulations and strategic partnerships. Founded by Dr. Yannis Alexandrides and his wife Eva, the brand initially developed a unique anti-oxidant, vitamin C-rich formula, NAC Y2, to aid post-operative skin recovery. Its success prompted a transition into everyday skincare, leading to significant retail expansion and, eventually, substantial investments from major players like Skky Partners and Estée Lauder Companies. This transformation underscores a commitment to medical-grade efficacy combined with luxury appeal, allowing 111Skin to navigate a competitive market while focusing on product quality and global reach.
Dr. Yannis Alexandrides, a distinguished facial plastic and reconstructive surgeon based on London's Harley Street, collaborated with biochemists in 2007 to develop an advanced healing solution for his patients. The resulting NAC Y2 formula, initially prescribed for its remarkable regenerative properties, quickly garnered widespread acclaim. Patients frequently requested more, citing visible improvements in their skin's appearance and health. This enthusiastic feedback inspired Dr. Yannis and Eva to adapt the formula for broader use, leading to the establishment of 111Skin in June 2010. Eva took charge of the brand's creative and marketing aspects, shaping its identity in the luxury skincare landscape.
A pivotal moment arrived in 2012 when Annalise Fard, a senior director at Harrods, discovered 111Skin through one of Dr. Yannis’s patients. Recognizing its potential as a highly effective post-surgery skincare line, Harrods became the brand's first stockist. Fard highlighted the blend of medical expertise, clinical effectiveness, and luxurious positioning as key factors that resonated with Harrods' clientele. This initial partnership proved highly successful, paving the way for 111Skin to expand its presence to 400 retailers and 140 spas globally. Products like the Repair Serum NAC Y2 and the Celestial Black Diamond Lifting and Firming Face Mask emerged as bestsellers, solidifying the brand's reputation.
The brand's continued growth attracted significant attention from investors. In January 2025, Kim Kardashian’s private equity firm, Skky Partners, acquired a minority stake in 111Skin. Following this, Estée Lauder Companies (ELC) also announced a minority investment, further validating the brand's market position. Dr. Yannis emphasized that these investments were strategic, aiming not just for capital but for expertise to support new product development, optimize existing offerings, and expand their community of loyal customers. The company reported impressive retail sales of £60 million in 2025, demonstrating a 27% year-on-year growth across multiple channels.
Post-investment, 111Skin plans to enhance its product portfolio and intensify its presence in key markets such as the UK, US, China, and Thailand. Eva Alexandrides noted that the Skky Partners investment enabled operational improvements, including better warehousing and upgraded internal software, allowing the brand to future-proof its business. Manufacturing has expanded to Europe and Asia, while formulation development remains in the UK. The association with Kim Kardashian, a known admirer of the brand since 2019, significantly boosted brand awareness, particularly through her extensive social media reach.
The skincare market, however, is increasingly saturated, posing a challenge for differentiation. Eva Alexandrides acknowledges that consumers face confusion amidst a plethora of choices, stressing the importance for brands to prioritize quality over fleeting trends. 111Skin addresses this by continuously innovating, as seen with their Celestial Black Diamond Eye Masks, a social media sensation since 2015, and their new Exosome Face Lift serum launched in September 2025. Dr. Yannis actively incorporates advancements from international surgical conferences into product development, ensuring innovation without sacrificing efficacy.
To combat market saturation and boost global visibility, a substantial portion of the ELC investment will be allocated to marketing. North America accounted for 42% of 111Skin’s sales last year, with Europe at 19%. Building on its success in the UK, the brand is now targeting the US market. A permanent clinic at New York’s Plaza Hotel, offering advanced facials and massages, is a strategic move to engage discerning US luxury consumers who value authenticity and provenance. The remaining 61% of sales come from the Middle East, China, and Thailand, regions where the brand has grown organically through word-of-mouth referrals from Dr. Yannis’s Harley Street practice, which serves a diverse international clientele. Chinese consumers, known for their early investment in science-based beauty, have shown strong loyalty, giving 111Skin a headstart in that market.
The journey of 111Skin from a clinical necessity to a globally recognized luxury skincare brand highlights the power of innovation, strategic partnerships, and a relentless focus on quality. The brand's ability to adapt to market challenges, leverage influential endorsements, and expand into diverse international markets underscores its robust growth trajectory. With renewed investment and a clear vision, Dr. Yannis and Eva Alexandrides are well-positioned to further scale their enterprise, remaining committed to their doctor-led principles and the creation of effective, high-performance skincare solutions for a discerning global clientele.
